• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

佐他莫司与依维莫司洗脱支架治疗真性冠状动脉慢性完全闭塞病变再通后的血管造影及临床结果比较

Zotarolimus compared with everolimus eluting stents-angiographic and clinical results after recanalization of true coronary chronic total occlusions.

作者信息

Markovic Sinisa, Lützner Michael, Rottbauer Wolfgang, Wöhrle Jochen

机构信息

Department of Internal Medicine II, University of Ulm, Germany.

出版信息

Catheter Cardiovasc Interv. 2016 Jul;88(1):18-23. doi: 10.1002/ccd.26482. Epub 2016 Mar 4.

DOI:10.1002/ccd.26482
PMID:26945903
Abstract

OBJECTIVES

To evaluate angiographic and clinical results of ZES compared with EES after recanalization of CTOs.

BACKGROUND

ZES and EES showed similar clinical results in non-CTO lesions. Whether ZES and EES are also comparable in true CTO lesions (TIMI 0 flow, duration of occlusion of more than 3 months) with a higher risk of restenosis has not been addressed so far.

METHODS

125 patients with successful CTO recanalization via antegrade or retrograde approach were included. EES were implanted in 68 patients and ZES in 57 patients. Dual antiplatelet therapy was prescribed for 12 months. Follow-up angiography was scheduled at 9 months and clinical follow-up at 12 months. The primary angiographic outcome measure was in-stent late lumen loss. Primary clinical outcome measures were target lesion revascularization rate (TLR) and major adverse cardiac events (MACE) as a composite of cardiac death, TLR and myocardial infarction not clearly attributable to a non-target vessel.

RESULTS

Baseline characteristics were similar in both groups. Mean stent length was 72.8 ± 33.0mm with EES and 70.8 ± 31.5 mm with ZES (P = 0.72). In-stent late lumen loss was 0.50 ± 0.71 mm for EES compared with 0.59 ± 0.72 (P = 0.52) for ZES. There were similar rates for TLR (EES 10.3% versus ZES 10.5%, P = 0.97) and MACE (EES 10.3% versus ZES 12.3%). No definite or probable stent thrombosis occurred. Stent length but not type of stent was predictive for in-stent late loss and TLR.

CONCLUSION

ZES and EES showed similar angiographic and clinical outcomes for treatment of CTOs. © 2016 Wiley Periodicals, Inc.

摘要

目的

评估慢性完全闭塞病变(CTO)再通后,佐他莫司洗脱支架(ZES)与依维莫司洗脱支架(EES)的血管造影结果及临床疗效。

背景

ZES和EES在非CTO病变中显示出相似的临床疗效。ZES和EES在再狭窄风险较高的真性CTO病变(心肌梗死溶栓试验(TIMI)0级血流,闭塞持续时间超过3个月)中是否具有可比性,目前尚未有相关研究。

方法

纳入125例通过顺行或逆行途径成功实现CTO再通的患者。其中68例患者植入EES,57例患者植入ZES。双联抗血小板治疗持续12个月。计划在9个月时进行随访血管造影,在12个月时进行临床随访。主要血管造影结局指标为支架内晚期管腔丢失。主要临床结局指标为靶病变血运重建率(TLR)和主要不良心脏事件(MACE),MACE为心脏死亡、TLR和不能明确归因于非靶血管的心肌梗死的复合事件。

结果

两组患者的基线特征相似。EES组的平均支架长度为72.8±33.0mm,ZES组为70.8±31.5mm(P = 0.72)。EES组的支架内晚期管腔丢失为0.50±0.71mm,ZES组为0.59±0.72mm(P = 0.52)。TLR(EES组为10.3%,ZES组为10.5%,P = 0.97)和MACE(EES组为10.3%,ZES组为12.3%)的发生率相似。未发生明确或可能的支架血栓形成。支架长度而非支架类型可预测支架内晚期丢失和TLR。

结论

ZES和EES在治疗CTO方面显示出相似的血管造影和临床结局。©2016威利期刊公司。

相似文献

1
Zotarolimus compared with everolimus eluting stents-angiographic and clinical results after recanalization of true coronary chronic total occlusions.佐他莫司与依维莫司洗脱支架治疗真性冠状动脉慢性完全闭塞病变再通后的血管造影及临床结果比较
Catheter Cardiovasc Interv. 2016 Jul;88(1):18-23. doi: 10.1002/ccd.26482. Epub 2016 Mar 4.
2
Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.随机多中心试验研究比较在慢性完全闭塞病变中应用可降解聚合物载紫杉醇药物洗脱支架与应用不可降解聚合物载依维莫司药物洗脱支架的血管造影结果:PRISON IV 试验。
JACC Cardiovasc Interv. 2017 Jan 23;10(2):133-143. doi: 10.1016/j.jcin.2016.10.017.
3
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).全患者人群行经皮冠状动脉介入治疗后第一代或第二代药物洗脱支架或裸金属支架植入术后 2 年的结果:来自 PRODIGY 研究(支架内内膜增生分级后延长双联抗血小板治疗研究)的预先指定分析。
JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11.
4
Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions).依维莫司洗脱支架在慢性完全闭塞血运重建中的安全性和有效性:来自 EXPERT CTO 多中心试验(依维莫司药物洗脱冠状动脉支架在慢性完全闭塞病变中的应用、表现和技术评估)的结果。
JACC Cardiovasc Interv. 2015 May;8(6):761-769. doi: 10.1016/j.jcin.2014.12.238. Epub 2015 Apr 22.
5
Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.重叠使用第二代药物洗脱支架治疗长冠状动脉病变患者的两年临床结果:依维莫司洗脱支架与佐他莫司洗脱支架的比较
Coron Artery Dis. 2014 Aug;25(5):405-11. doi: 10.1097/MCA.0000000000000098.
6
Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.佐他莫司洗脱Resolute Integrity支架与依维莫司洗脱Xience Xpedition支架治疗超长(>30mm)原发冠状动脉狭窄的对比研究
Cardiovasc Revasc Med. 2017 Apr-May;18(3):160-164. doi: 10.1016/j.carrev.2016.12.007. Epub 2016 Dec 15.
7
A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).糖尿病患者中依维莫司洗脱冠状动脉支架与西罗莫司洗脱冠状动脉支架的10个月血管造影和4年临床结果(DiabeDES IV随机血管造影试验)
Catheter Cardiovasc Interv. 2015 Dec 1;86(7):1161-7. doi: 10.1002/ccd.25875. Epub 2015 May 6.
8
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.随机治疗所有患者的瑞波西利洗脱 Resolute Integrity 和依维莫司洗脱 PROMUS Element 冠状动脉支架 5 年结果:DUTCH PEERS(TWENTE II)试验的最终报告。
JACC Cardiovasc Interv. 2018 Mar 12;11(5):462-469. doi: 10.1016/j.jcin.2017.11.031.
9
Angiographic and clinical outcomes after recanalization of coronary chronic total occlusions with the Orsiro sirolimus-eluting stent compared with the resolute zotarolimus-eluting stent.
Coron Artery Dis. 2017 Aug;28(5):376-380. doi: 10.1097/MCA.0000000000000470.
10
Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison.生物可吸收支架与依维莫司洗脱支架治疗慢性冠状动脉完全闭塞的比较:配对比较的临床和血管造影结果
Coron Artery Dis. 2017 Mar;28(2):120-125. doi: 10.1097/MCA.0000000000000449.

引用本文的文献

1
Five-year clinical outcomes of first-generation versus second-generation drug-eluting stents following coronary chronic total occlusion intervention.冠状动脉慢性完全闭塞病变介入治疗后第一代与第二代药物洗脱支架的五年临床结局
J Geriatr Cardiol. 2019 Aug;16(8):639-647. doi: 10.11909/j.issn.1671-5411.2019.08.006.